- Report
- February 2025
- 133 Pages
Global
From €3973EUR$4,365USD£3,406GBP
€4414EUR$4,850USD£3,784GBP
- Report
- August 2024
- 149 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- January 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2024
- 180 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- January 2025
- 146 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- December 2023
- 353 Pages
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- December 2021
- 226 Pages
Global
From €2389EUR$2,625USD£2,048GBP
€4778EUR$5,250USD£4,096GBP
- Report
- June 2023
- 155 Pages
Global
From €4232EUR$4,650USD£3,628GBP
- Report
- March 2019
- 255 Pages
Global
From €1126EUR$1,238USD£966GBP
€2253EUR$2,475USD£1,931GBP
- Report
- June 2023
- 150 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- November 2023
- 190 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- April 2023
- 111 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Book
- February 2024
- 160 Pages
The Epigenetic Diagnostics market is a subset of the larger Genomics market. It focuses on the study of epigenetic changes, which are modifications to the genome that do not involve changes to the underlying DNA sequence. These changes can be used to diagnose and treat a variety of diseases, including cancer, neurological disorders, and autoimmune diseases. Epigenetic diagnostics can also be used to identify individuals at risk for certain diseases, allowing for earlier intervention and better outcomes.
Epigenetic diagnostics is a rapidly growing field, with a wide range of applications. Companies in the market include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, and Oxford Nanopore Technologies. Show Less Read more
